PIH26 COST EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS AMONG EXTREME PRETERM INFANTS (29 WEEKS OF GESTATIONAL AGE) AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
May 1, 2020, 00:00 AM
10.1016/j.jval.2020.04.421
https://www.valueinhealthjournal.com/article/S1098-3015(20)30609-4/fulltext
Section Title :
Section Order :
10293
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30609-4&doi=10.1016/j.jval.2020.04.421